Intercure Ltd.
For the period ended Nov 3, 2025. Filed Nov 3, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Nov 3, 2025 · Filed Nov 3, 2025
Use the contents to explore the available documents and sections.
Contents
INTERCURE LTD
(Translation of registrant’s name into English)
85 Medinat ha-Yehudim Street
Herzliya, 4676670, Israel
Tel: +972 77 460 5012
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On November 3, 2025, InterCure Ltd. issued a press release titled “InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.
| Exhibit No. | |
|---|---|
| 99.1 | Press Release issued by InterCure Ltd. on November 3, 2025, titled “InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation.” |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.